Fibrosis is a common lesion in different pathological conditions and it is defined by the excessive accumulation of collagen and other extracellular matrix proteins in the connective tissue of different organs where it causes organ dysfunction. Collagen corresponds around of 30% of all proteins in humans, and is the major extracellular protein of different organs such as the skin, cartilage, bones, teeth and cornea.
To prevent this collagen accumulation, proteases are used. Proteases target many substrates, thus inflicting changes in distinct biological processes correlated with fibrosis.
At present, there is still a need to provide protease carriers or vehicles capable of achieving a constant and continuous release of the proteases encapsulated within at therapeutic doses during a sufficient period of time for the treatment of diseases which require a sustained protease administration during treatment periods greater than one week.
A Spanish research team from a of a university hospital and a Spanish university are working on biomedical research in biomaterials and biomedicine. The hospital team works on the rheumatology and dermatology department and the university professor on smart biomaterials for pharmaceutical used. They have developed a nanocapsule compositions capable of releasing agents. The agents, proteases of therapeutic interest, can be released with a controlled kinetic and a prolonged and sustainable effect over time.
The controlled and sustained released solves the above mentioned problems for treatments that last more than one week. It provides sustained release polymeric nanocapsules capable of releasing proteases such as collagenase with a controlled kinetic and a prolonged and sustainable effect over time.
The team is looking for license agreement. They are looking for pharmaceutical or biotechnology companies working on biomolecules, nanocapsules or nanoparticules, to license the patent. It will be desired if they have interest in fibrosis treatment.